Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of intra-arterial locoregional doxorubicin and docetaxel with systemic neoadjuvant chemotherapy in locally advanced breast cancer
2012-002709-23Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin and docetaxel in breast cancer (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Incidence of adverse events. Started Oct 2012; status: completed.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002709-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002709-23.